Condition: Chronic Lymphocytic Leukemia · Sponsor: BeOne Medicines
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
This description comes directly from the study's public registry record.
Study Director · 8778285568 · clinicaltrials@beonemed.com
Always discuss trial participation with your own doctor first.
| Stanford Cancer Institute | Palo Alto, California, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Fred Hutchinson Cancer Research Center | Seattle, Washington, United States | Recruiting |
| Blacktown Cancer and Haematology Centre | Blacktown, New South Wales, Australia | Recruiting |
| Concord Repatriation General Hospital | Concord, New South Wales, Australia | Recruiting |
| Genesiscare North Shore | St Leonards, New South Wales, Australia | Recruiting |
| Princess Alexandra Hospital | Woolloongabba, Queensland, Australia | Recruiting |
| Monash Health | Clayton, Victoria, Australia | Recruiting |
| Austin Health | Heidelberg, Victoria, Australia | Recruiting |
| Cabrini Hospital Malvern | Malvern, Victoria, Australia | Recruiting |
| The Alfred Hospital | Melbourne, Victoria, Australia | Recruiting |
| Instituto Dor de Pesquisa E Ensino Distrito Federal | Brasília, Brazil | Recruiting |
+ 79 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07277231